VERU Stock Forecast: Veru, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.94
−8.06% on the day

The median 12-month analyst price target for Veru, Inc. is $25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 51 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$36.0M
Ticker Nerd rank
51/ 100
Median analyst target
$25
Analysts covering
3
Revenue$0.0
Operating income−$7.7M
Net income−$7.0M
Free cash flow−$5.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.2%
1M
−18.5%
YTD
−9.3%
1Y
−13.0%
From 52W high
−54.1%
From 52W low
0.0%
$1.94
$4.23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Veru, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
51/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
81
Revisions
62
Volatility
61
Issuance
48
Quality
45
Momentum
39
Value
30
Accruals
21

Growth (81): Sales and profits are climbing, and climbing faster than before.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VERU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VERU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00Jan 26Apr 26Jul 26Oct 26VERUHigh $28Median $25Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$24
Low
$25
Median
$28
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Oct 2026WestPark CapitalInitiatesBuy$28
4 June 2026Canaccord GenuityMaintainsBuy$25
15 May 2026OppenheimerMaintainsOutperform—
18 Dec 2025Canaccord GenuityInitiatesBuy—
13 Aug 2025Raymond JamesMaintainsOutperform—
2 Jan 2025HC Wainwright & Co.ReiteratesBuy—
20 Dec 2024HC Wainwright & Co.ReiteratesBuy—
5 Nov 2024OppenheimerReiteratesOutperform—
14 May 2024B. Riley SecuritiesInitiatesBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.MaintainsBuy—
15 Apr 2024OppenheimerReiteratesOutperform—
28 Mar 2024Raymond JamesInitiatesOutperform—
8 Feb 2024HC Wainwright & Co.ReiteratesBuy—
27 Sept 2023HC Wainwright & Co.ReiteratesBuy—
7 June 2023JefferiesUpgradeHold—
15 May 2023HC Wainwright & Co.MaintainsBuy—
8 May 2023HC Wainwright & Co.ReiteratesBuy—
12 Apr 2023HC Wainwright & Co.ReiteratesBuy—
6 Apr 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VERU.

Market Radar

This page is one stock. Monday covers all of them.

VERU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VERU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Veru, Inc. returned −13.0% against +6.9% for the S&P 500, dividends included.

VERU vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Jan 26Apr 26Jul 26Oct 26VERUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VERU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.2×

Cheaper than 62% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−64.5%

Higher than 18% of US stocks

Return on assets
−54.0%

Higher than 7% of US stocks

Dividend yield
13.7%

Higher than 91% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Veru, Inc. has a market value of $36.0M and an enterprise value of $12.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$13.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$26.0M, after $0.0 of capital spending.

  • Shares outstanding: 17.1M.

  • Forward dividend yield: 13.73%.

  • Veru, Inc. employs 20 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

VERU and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VERUVeru, Inc.$36.0M51
ATNMActinium Pharmaceuticals, Inc.$32.9M87
GRDXGridAI Technologies Corp.$32.4M16
HYFTMindWalk Holdings Corp.$32.0M44
CUECue Biopharma, Inc.$34.7M20
HYPDHyperion DeFi, Inc.$31.5M39
FLNAFilana Therapeutics, Inc.$31.0M66

Take a look at VERU’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Veru, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VERU

What is the VERU stock price forecast for 2026-2027?

The median 12-month analyst price target for Veru, Inc. is $25, with estimates ranging from $24 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VERU stock a buy right now?

Of the 3 analysts covering Veru, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Veru, Inc. 51 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VERU?

As at 21 Nov 2026, Veru, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (81 of 100).

Will VERU stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $25, and Ticker Nerd's factor model ranks Veru, Inc. 51 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VERU stock forecast for 2030?

No analyst covering Veru, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VERU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $28 over the next 12 months.

How has VERU stock performed over the past year?

Veru, Inc. returned -13.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Veru, Inc. do?

Veru Inc. is a late-stage biopharmaceutical company focused on developing and commercializing medicines for cardiometabolic and inflammatory diseases. The company’s current programs center on enobosarm, an oral selective androgen receptor modulator being studied for muscle preservation and body composition support in weight-loss settings, and sabizabulin, an oral anti-inflammatory candidate being developed for severe viral lung disease and other inflammatory conditions.

Company

About Veru, Inc.

Veru Inc. is a late-stage biopharmaceutical company focused on developing and commercializing medicines for cardiometabolic and inflammatory diseases. The company’s current programs center on enobosarm, an oral selective androgen receptor modulator being studied for muscle preservation and body composition support in weight-loss settings, and sabizabulin, an oral anti-inflammatory candidate being developed for severe viral lung disease and other inflammatory conditions. Veru also markets FC2, a female condom designed to provide dual protection against unintended pregnancy and sexually transmitted infections. Based in Miami, Florida, Veru serves both clinical and consumer health markets through a portfolio that combines prescription drug development with sexual health products. Its work spans obesity-related care, oncology research, respiratory complications, and reproductive health, placing it at the intersection of specialty pharmaceuticals and medical consumer products.

CEO Dr. Mitchell S. Steiner F.A.C.S., M.D. · 20 employees · United States · https://verupharma.com